{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:55:53Z","timestamp":1773896153099,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1053\/j.seminoncol.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T17:19:46Z","timestamp":1556126386000},"page":"112-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["State of the science in smoldering myeloma: Should we be treating in the clinic?"],"prefix":"10.1053","volume":"46","author":[{"given":"Elizabeth","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Dew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2019.03.001_bib0001","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0002","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0004","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0006","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0007","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0008","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0009","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0012","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation","volume":"4","author":"Durie","year":"2003","journal-title":"Hematol J"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0013","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0014","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(14)70001-8","article-title":"Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study","volume":"1","author":"Kyle","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0016","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0018","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0019","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2013a randomized study. Myeloma Group of Western Sweden.","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0021","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0022","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0024","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0025","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","article-title":"Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma","volume":"1","author":"Mailankody","year":"2017","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0026","first-page":"402-","article-title":"Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) As Induction followed By HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"130","author":"Mateos","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0027","doi-asserted-by":"crossref","first-page":"976-","DOI":"10.1182\/blood.V128.22.976.976","article-title":"Phase II Trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0028","first-page":"510-","article-title":"Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study","volume":"130","author":"Hofmeister","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2019.03.001_bib0029","unstructured":"FDA Alerts healthcare professionals and oncology clinical investigators about two clinical trials on hold evaluating KEYTRUDA (pembrolizumab) in patients with multiple myeloma2017. athttps:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm574305.htm.)"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418302045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418302045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:55:41Z","timestamp":1758804941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775418302045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0093775418302045"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.03.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the science in smoldering myeloma: Should we be treating in the clinic?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}